% | $
Quotes you view appear here for quick access.

Santarus, AŞ Message Board

  • immunotecde immunotecde Aug 1, 2013 2:12 PM Flag

    Good news for Santarus

    Ruconest is out of competition with VPHM
    Check out HALO news! Ph2 study cancelled by VPHM

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is great. SNTS may look for prophylactic HAE indication also. Also pancreatic indication may be pursued. VPHM product is from human blood and needs careful purification. Ruconest will be cheaper. SNTS is still our little baby. We really could head to $40's+ if Ruconest gets approved. Uceris is growing nicely, already approaching the rate of $100 million per year sales on script counts. This gem is going to KABOOM again!!!!!!!

      Sentiment: Strong Buy

    • ViroPharma Provides Update On Phase 2 Clinical Evaluation Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
      EXTON, Pa., Aug. 1, 2013 /PRNewswire/ — ViroPharma Incorporated (NASDAQ: VPHM) today announced that following discussion with the Center for Biologics Evaluation and Research (CBER) division of the U.S. Food and Drug Administration, ViroPharma is going to discontinue this Phase 2 study. The discontinuation of the study is a precaution related to the emergence of an unexpected incidence and titer of non-neutralizing anti-rHuPH20 antibodies in a number of patients with the formulation being used in this study. These antibodies have not been associated with any adverse clinical effects and are of unknown clinical significance.
      Cinryze is approved in the United States as intravenous (IV) administration for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), and in Europe for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks in adolescent and adult patients with HAE.
      Indeed good news for SNTS!! Solid safety profile of Ruconest.. here we go!

      Sentiment: Strong Buy